Need Immediate Care?

Find Urgent Care Locations

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Short Title: S2308

Enrollment Status: Recruiting

NCT #: NCT06337318

Specialty Area: Oncology

Condition Studied: Follicular Lymphoma

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

The purpose of this study is to compare the usual treatment (rituximab) to using the study drug mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. The study doctors will be looking to see if the study drug increases the time patients live with lymphoma before it gets worse.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Must have a histologically confirmed diagnosis of Classic Follicular Lymphoma
Must have low-tumor burden follicular lymphoma
Must have Ann Arbor stage II, III, or IV follicular lymphoma
No Follicular Lymphoma with “blastoid” or “large centrocyte” cytological features, or Follicular large B-cell lymphoma

What's Involved

Participation in the study will include:

Random assignment to receive either rituximab, the usual drug used to treat this cancer, or mosunetuzumab, the study drug
Rituximab given through a vein for the first dose, then as an injection under the skin for later doses, for participants assigned to that group
Mosunetuzumab given as an injection under the skin, for participants assigned to that group
Imaging with computed tomography (CT) scans and/or positron emission tomography (PET) scans
Blood sample collection

Principal Investigator

Harry Menon DO, MPH

Oncology

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06337318

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.